Moving forward in clinical research with master protocols

Jay J H Park, Louis Dron, Edward J Mills, Jay J H Park, Louis Dron, Edward J Mills

Abstract

With billions of dollars in research and development (R&D) funding continuing to be invested, the novel coronavirus disease 2019 (COVID-19) has become into a singular focus for the scientific community. However, the collective response from the scientific communities have seen poor return on investment, particularly for therapeutic research for COVID-19, revealing the existing weaknesses and inefficiencies of the clinical trial enterprise. In this article, we argue for the importance of structural changes to existing research programs for clinical trials in light of the lessons learned from COVID-19.

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Copyright © 2021 Elsevier Inc. All rights reserved.

References

    1. Park J.J.H., Mogg R., Smith G.E., Nakimuli-Mpungu E., Jehan F., Rayner C.R., Condo J., Decloedt E.H., Nachega J.B., Reis G., Mills E.J. How COVID-19 has fundamentally changed clinical research in global health. Lancet Glob. Health. 2021;9(5):e711–e720.
    1. Bugin K., Woodcock J. Trends in COVID-19 therapeutic clinical trials. Nat. Rev. Drug Discov. 2021;20(4):254–255.
    1. Tikkinen K.A., Malekzadeh R., Schlegel M., Rutanen J., Glasziou P. COVID-19 clinical trials: learning from exceptions in the research chaos. Nat. Med. 2020;26(11):1671–1672. Nov.
    1. Siemieniuk R.A., Bartoszko J.J., Ge L., Zeraatkar D., Izcovich A., Kum E., Pardo-Hernandez H., Rochwerg B., Lamontagne F., Han M.A., Liu Q., Agarwal A., Agoritsas T., Chu D.K., Couban R., Darzi A., Devji T., Fang B., Fang C., Flottorp S.A., Foroutan F., Ghadimi M., Heels-Ansdell D., Honarmand K., Hou L., Hou X., Ibrahim Q., Khamis A., Lam B., Loeb M., Marcucci M., McLeod S.L., Motaghi S., Murthy S., Mustafa R.A., Neary J.D., Qasim A., Rada G., Riaz I.B., Sadeghirad B., Sekercioglu N., Sheng L., Sreekanta A., Switzer C., Tendal B., Thabane L., Tomlinson G., Turner T., Vandvik P.O., Vernooij R.W., Viteri-Garcia A., Wang Y., Yao L., Ye Z., Guyatt G.H., Brignardello-Petersen R., Qasim A., Martinez J.P.D., Cusano E. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020;370:m2980.
    1. RECOVERY Collaborative Group Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 2021;384(8):693–704. Feb 25.
    1. Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., Zingman B.S., Kalil A.C., Hohmann E., Chu H.Y., Luetkemeyer A., Kline S., Lopez de Castilla D. Remdesivir for the treatment of Covid-19. N. Engl. J. Med. 2020;383(19):1813–1826. Nov 5.
    1. Angus D.C., Derde L., Al-Beidh F., Annane D., Arabi Y., Beane A., van Bentum-Puijk W., Berry L., Bhimani Z., Bonten M., Bradbury C. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324(13):1317–1329. Oct 6.
    1. Angus D.C., Berry S., Lewis R.J., Al-Beidh F., Arabi Y., van Bentum-Puijk W., Bhimani Z., Bonten M., Broglio K., Brunkhorst F., Cheng A.C. The REMAP-CAP (randomized embedded multifactorial adaptive platform for community-acquired pneumonia) study. rationale and design. Ann. Am. Thorac. Soc. 2020;17(7):879–891. Jul.
    1. Reis G., Silva E. Moreira, Silva D.C. Medeiros, Thabane L., Singh G., Park J.J.H., Forrest J.I., Harari O., Santos C.V. Quirino Dos, de Almeida A.P.F. Guimaraes, Neto A.D. Figueiredo, Savassi L.C.M., Milagres A.C., Teixeira M.M., Simplicio M.I.C., Ribeiro L.B., Oliveira R., Mills E.J., T. Investigators Effect of early treatment with hydroxychloroquine or lopinavir and ritonavir on risk of hospitalization among patients with Covid-19: the TOGETHER randomized clinical trial. JAMA Netw. Open. 2021;4(4):e216468.
    1. P.T.C. Group Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021;397(10279):1063–1074.
    1. Woodcock J., LaVange L.M. Master protocols to study multiple therapies, multiple diseases, or both. N. Engl. J. Med. 2017;377(1):62–70.
    1. Angus D.C., Alexander B.M., Berry S., Buxton M., Lewis R., Paoloni M., Webb S.A.R., Arnold S., Barker A., Berry D.A., Bonten M.J.M., Brophy M., Butler C., Cloughesy T.F., Derde L.P.G., Esserman L.J., Ferguson R., Fiore L., Gaffey S.C., Gaziano J.M., Giusti K., Goossens H., Heritier S., Hyman B., Krams M., Larholt K., LaVange L.M., Lavori P., Lo A.W., London A.J., Manax V., McArthur C., O’Neill G., Parmigiani G., Perlmutter J., Petzold E.A., Ritchie C., Rowan K.M., Seymour C.W., Shapiro N.I., Simeone D.M., Smith B., Spellberg B., Stern A.D., Trippa L., Trusheim M., Viele K., Wen P.Y., Woodcock J., C. The Adaptive Platform Trials Adaptive platform trials: definition, design, conduct and reporting considerations. Nat. Rev. Drug Discov. 2019;18(10):797–807.
    1. Cecchini M., Rubin E.H., Blumenthal G.M., Ayalew K., Burris H.A., Russell-Einhorn M., Dillon H., Lyerly H.K., Reaman G.H., Boerner S., LoRusso P.M. Challenges with novel clinical trial designs: master protocols. Clin. Cancer Res. 2019;25(7):2049–2057.
    1. Renfro L.A., Sargent D.J. Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. Ann. Oncol. 2017;28(1):34–43.
    1. Lee K.M., Brown L.C., Jaki T., Stallard N., Wason J. Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveats. Trials. 2021;22(1):1–10.
    1. Hague D., Townsend S., Masters L., Rauchenberger M., Van Looy N., Diaz-Montana C., Gannon M., James N., Maughan T., Parmar M.K. Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons. Trials. 2019;20(1):294.
    1. Schiavone F., Bathia R., Letchemanan K., Masters L., Amos C., Bara A., Brown L., Gilson C., Pugh C., Atako N. This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols. Trials. 2019;20(1):264.
    1. Morrell L., Hordern J., Brown L., Sydes M.R., Amos C.L., Kaplan R.S., Parmar M.K., Maughan T.S. Mind the gap? The platform trial as a working environment. Trials. 2019;20(1):1–6.
    1. Park J.J.H., Siden E., Zoratti M.J., Dron L., Harari O., Singer J., Lester R.T., Thorlund K., Mills E.J. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials. 2019;20(1):572.
    1. Park J.J.H., Grais R.F., Taljaard M., Nakimuli-Mpungu E., Jehan F., Nachega J.B., Ford N., Xavier D., Kengne A.P., Ashorn P., Socias M.E., Bhutta Z.A., Mills E.J. Urgently seeking efficiency and sustainability of clinical trials in global health. Lancet Glob. Health. 2021;9(5):e681–e690.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다